Innate Pharma SA
Business
Innate Pharma SA is a global, clinical-stage biotechnology company developing immunotherapies that harness the innate immune system, with a particular focus on Natural Killer (NK) cell‑based approaches. It develops therapeutic antibodies, multi‑specific ANKET® NK cell engagers, antibody‑drug conjugates and related biologics, including proprietary programs such as lacutamab, monalizumab and multiple IPH‑series candidates. Its business is organized around discovery and clinical development, a proprietary ANKET® platform, ADC research and partnered programs with biopharmaceutical collaborators. The company conducts clinical trials and advances programs through collaborations and licensing across the United States, Europe and other international markets.
Summary from filing dated 2025-04-30
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-49.18M |
| Total assets | $62.72M |
| Total liabilities | — |
| Stockholders' equity | — |
| Operating cash flow | — |